Biomedical Engineering Reference
In-Depth Information
45. Tonino, R.P., Meunier, P.J., Emkey, R., Rodriguez-Portales, J.A., Menkes, C.J., Wasnich, R.D.,
Bone, H.G., Santora, A.C., Wu, M., Desai, R., Ross, P.D.: Skeletal benefits of alendronate:
7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study
group. J. Clin. Endocrinol. Metab. 85, 3109-3115 (2000)
46. Goh, S.K., Yang, K.Y., Koh, J.S., Wong, M.K., Chua, S.Y., Chua, D.T., Howe, T.S.:
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone
Joint Surg. Br. 89, 349-353 (2007)
47. Lenart, B.A., Lorich, D.G., Lane, J.M.: Atypical fractures of the femoral diaphysis in
postmenopausal women taking alendronate. N. Engl. J. Med. 358, 1304-1306 (2008)
48. Capeci, C.M., Tejwani, N.C.: Bilateral low-energy simultaneous or sequential femoral
fractures in patients on long-term alendronate therapy. J. Bone Joint Surg. Am. 91, 2556-
2561 (2009)
49. Neviaser, A.S., Lane, J.M., Lenart, B.A., Edobor-Osula, F., Lorich, D.G.: Low-energy
femoral shaft fractures associated with alendronate use. J. Orthop. Trauma 22, 346-350
(2008)
50. Arneson, T.J., Melton 3rd, L.J., Lewallen, D.G., O'Fallon, W.M.: Epidemiology of
diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965-1984. Clin. Orthop.
Relat. Res. 234, 188-194 (1988)
51. Salminen, S., Pihlajamaki, H., Avikainen, V., Kyro, A., Bostman, O.: Specific features
associated with femoral shaft fractures caused by low-energy trauma. J. Trauma 43, 117-
122 (1997)
52. Salminen, S.T., Pihlajamaki, H.K., Avikainen, V.J., Bostman, O.M.: Population based
epidemiologic and morphologic study of femoral shaft fractures. Clin. Orthop. Relat. Res.
372, 241-249 (2000)
53. Black, D.M., Kelly, M.P., Genant, H.K., Palermo, L., Eastell, R., Bucci-Rechtweg, C.,
Cauley, J., Leung, P.C., Boonen, S., Santora, A., de Papp, A., Bauer, D.C.: Bisphosphonates
and fractures of the subtrochanteric or diaphyseal femur. N. Engl J. Med. 362, 1761-1771
(2010)
54. Bone, H.G., Hosking, D., Devogelaer, J.-P., Tucci, J.R., Emkey, R.D., Tonino, R.P.,
Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., Liberman, U.A.: The
alendronate phase III osteoporosis treatment study group. Ten years' experience with
alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189-1199
(2004)
55. Allen, M.R., Burr, D.B.: Three years of alendronate treatment results in similar levels of
vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22, 1759-1765
(2007)
56. Mashiba, T., Hirano, T., Turner, C.H., Forwood, M.R., Johnston, C.C., Burr, D.B.:
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and
reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15, 613-620 (2000)
57. Mashiba, T., Turner, C.H., Hirano, T., Forwood, M.R., Johnston, C.C., Burr, D.B.: Effects
of suppressed bone turnover by bisphosphonates on microdamage accumulation and
biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28, 524-531
(2001)
58. Boivin, G.Y., Chavassieux, P.M., Santora, A.C., Yates, J., Meunier, P.J.: Alendronate
increases bone strength by increasing the mean degree of mineralization of bone tissue in
osteoporotic women. Bone 27, 687-694 (2000)
59. Burr, D.B., Miller, L., Grynpas, M., Li, J.L., Boyde, A., Mashiba, T., Hirano, T., Johnston,
C.C.: Tissue mineralization is increased following 1-year treatment with high doses of
bisphosphonates in dogs. Bone 33, 960-969 (2003)
60. Roschger, P., Rinnerthaler, S., Yates, J., Rodan, G.A., Fratzl, P., Klaushofer, K.:
Alendronate increases degree and uniformity of mineralization in cancellous bone and
decreases the porosity in cortical bone of osteoporotic women. Bone 29, 185-191 (2001)
61. Borah, B., Dufresne, T.E., Ritman, E.L., Jorgensen, S.M., Liu, S., Chmielewski, P.A.,
Phipps, R.J., Zhou, X., Sibonga, J.D., Turner, R.T.: Long-term risedronate treatment
Search WWH ::
Custom Search